New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Having an mRNA COVID vaccine will not make your body produce new tumour-fighting T cells. What it might do, based on this early research, is make dendritic cells more likely to notice a tumour and ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing. “After a ...

The federal government is cutting $500 million in research money for development of mRNA vaccines, which were widely used against the COVID-19 virus. Health Secretary Robert F. Kennedy Jr. said in a ...

With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives. That same mRNA-powered approach to medicine—in which synthetic mRNA is ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...